Liquidia Corp
Research Liquidia Corp (LQDA) on Bullrun: valuation model: 89.9% overvalued, market cap USD 6.68B, P/E 530.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLQDA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal89.9% overvalued
- Market capUSD 6.68B
- P/E530.5
- Financial periodFY2025
- RevenueUSD 158.32M
- Revenue growth1031.2%
- Net income-USD 68.92M
- Free cash flow-USD 40.02M
Valuation Snapshot
Bullrun's latest valuation model marks Liquidia Corp as 89.9% overvalued; latest market cap is USD 6.68B; P/E is 530.5.
About Liquidia Corp
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Frequently asked questions
Is Liquidia Corp overvalued or undervalued?
Bullrun's valuation model currently marks Liquidia Corp as 89.9% overvalued.
What is Liquidia Corp's market cap?
Liquidia Corp's market capitalization is USD 6.68B.
What is Liquidia Corp's P/E ratio?
Liquidia Corp's price-to-earnings (P/E) ratio is 530.5.
What does Liquidia Corp do?
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.